Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Feb 21, 2019- Data presented at ATTD confirms previous analyses that higher rates of scanning with the FreeStyle Libre system are strongly associated with improved glucose control- Prolonged hypoglycemia reduced by up to 56 percent if users scan a second time within an hour of low glucose readings- Trend arrow readings before meals can help identify glucose levels that can potentially be used to adjust treatment and address after meal hyperglycemia
- Feb 20, 2019Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products
- Feb 20, 2019- New point-of-care rapid test identifies and helps make effective care more accessible for millions of people living with hepatitis B, in support of World Health Organization (WHO) hepatitis targets- Life-changing test has obtained CE Mark and is now available in Europe, Africa, Asia, Latin America, and other countries that recognize CE Mark
- Jan 23, 2019- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent- Issues financial outlook for 2019, reflecting double-digit EPS growth and 6.5 to 7.5 percent organic sales growth
- Jan 21, 2019With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation
-
Jan 19, 2019- Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR™ stimulation- Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices- Additional data further showed switching from other types of SCS therapies to Abbott’s BurstDR stimulation significantly reduced pain and the need for opioid medication
- Jan 17, 2019LONG-TERM AGREEMENT BETWEEN JAPANESE RED CROSS SOCIETY AND ABBOTT BRINGS TOGETHER TWO GLOBAL LEADERS IN BLOOD AND PLASMA SCREENING, HELPING ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY ACROSS JAPAN
- Jan 16, 2019Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment
- Jan 14, 2019- First and only minimally invasive, transcatheter treatment specifically approved for premature babies with a patent ductus, a life-threatening opening in their heart- Nearly 12,000 very low birth weight babies are born in the U.S. each year with a persistent opening in their heart that requires medical intervention[1,2,3]- Life-saving technology provides new and optimally-sized treatment option to address critical need for the tiniest newborns, including premature infants weighing as little as two pounds